PriceTargets.com logo

MIRA Pharmaceuticals - MIRA Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $14.00
  • Forecasted Upside: 1,208.41%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 1 Strong Buy Ratings
$1.07 As of 12/17/2024 01:00 AM ET
▼ -0.03 (-2.73%)

This chart shows the closing price for MIRA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New MIRA Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MIRA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MIRA

Analyst Price Target is $14.00
▲ +1,208.41% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for MIRA Pharmaceuticals in the last 3 months. The average price target is $14.00, with a high forecast of $17.00 and a low forecast of $11.00. The average price target represents a 1,208.41% upside from the last price of $1.07.

This chart shows the closing price for MIRA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 3 investment analysts is to buy stock in MIRA Pharmaceuticals.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/26/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/24/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/23/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/22/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/20/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/18/2024
  • 1 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/17/2024
  • 1 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/17/2024

Latest Recommendations

  • 1 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
9/30/2024RODMAN&RENSHAWUpgradeStrong-Buy
9/30/2024Rodman & RenshawInitiated CoverageBuy$17.00
8/5/2024Ascendiant Capital MarketsInitiated CoverageBuy$11.00
(Data available from 12/18/2019 forward)

News Sentiment Rating

0.62 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/22/2024
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/21/2024
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/21/2024
  • 6 very positive mentions
  • 16 positive mentions
  • 2 negative mentions
  • 2 very negative mentions
Mentions as of
8/20/2024
  • 1 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
9/19/2024
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/19/2024
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
11/18/2024
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/18/2024

Current Sentiment

  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

MIRA Pharmaceuticals logo
MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Miami, Florida.
Read More

Today's Range

Now: $1.07
Low: $1.04
High: $1.12

50 Day Range

MA: $1.36
Low: $1.05
High: $2.20

52 Week Range

Now: $1.07
Low: $0.51
High: $5.01

Volume

356,087 shs

Average Volume

2,063,962 shs

Market Capitalization

$17.72 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.93

Frequently Asked Questions

What sell-side analysts currently cover shares of MIRA Pharmaceuticals?

The following Wall Street analysts have issued stock ratings on MIRA Pharmaceuticals in the last twelve months: Ascendiant Capital Markets, Rodman & Renshaw, and RODMAN&RENSHAW.
View the latest analyst ratings for MIRA.

What is the current price target for MIRA Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for MIRA Pharmaceuticals in the last year. Their average twelve-month price target is $14.00, suggesting a possible upside of 1,208.4%. Rodman & Renshaw has the highest price target set, predicting MIRA will reach $17.00 in the next twelve months. Ascendiant Capital Markets has the lowest price target set, forecasting a price of $11.00 for MIRA Pharmaceuticals in the next year.
View the latest price targets for MIRA.

What is the current consensus analyst rating for MIRA Pharmaceuticals?

MIRA Pharmaceuticals currently has 2 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe MIRA will outperform the market and that investors should add to their positions of MIRA Pharmaceuticals.
View the latest ratings for MIRA.

What other companies compete with MIRA Pharmaceuticals?

Other companies that are similar to MIRA Pharmaceuticals include Aerovate Therapeutics, ESSA Pharma, Unicycive Therapeutics, PDS Biotechnology and ZIVO Bioscience. Learn More about companies similar to MIRA Pharmaceuticals.

How do I contact MIRA Pharmaceuticals' investor relations team?

The company's listed phone number is 737-289-0835 and its investor relations email address is [email protected]. The official website for MIRA Pharmaceuticals is mirapharmaceuticals.com. Learn More about contacing MIRA Pharmaceuticals investor relations.